

Special Issue

Current Progress in Radiotherapy and Particle Therapy of Cancer

Message from the Guest Editor

Particle radiation therapy, including proton, carbon ion, and other heavy ion modalities, represents a significant advancement in precision oncology. These therapies leverage the Bragg peak phenomenon for superior dose localization, minimizing exposure to surrounding healthy tissues. Carbon ion therapy (CIT), in particular, offers enhanced biological effectiveness due to its high linear energy transfer (LET), making it effective for radioresistant and deep-seated tumors. Proton therapy, with increasing global accessibility, remains a standard in pediatric and select adult cancers. Recent innovations in treatment planning, image guidance, and delivery systems are improving therapeutic outcomes across all particle modalities. We welcome submissions for a Special Issue focusing on contemporary developments in radiotherapy, with an emphasis on particle therapies. Topics may include:

- Clinical outcomes in proton and heavy ion therapy;
- Advances in technology and treatment planning;
- Radiobiological insights and high-LET mechanisms;
- Integration with systemic and immunotherapies;
- Health economics and global access.

Guest Editor

Dr. Carla Hajj
Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Deadline for manuscript submissions

16 June 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/240659

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)